© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Growing up in an age where China steadily ramped up its chemical production, I witnessed a striking shift: what was once a regional supply for niche oxidizing agents like periodic acid transformed into a global juggernaut. China’s chemical manufacturing hubs—anchored in Jiangsu, Zhejiang, and Shandong—have pushed the limits on both volume and cost efficiency. The reason for this is rooted in unrestricted access to sodium periodate, potassium permanganate, and other necessary raw materials sourced from domestic mining and processing enterprises scattered throughout the vast Chinese landscape. Prices have held a competitive edge due to cheaper electricity, government-supported infrastructure, and lower shipping rates—factors interwoven with strong supply networks and logistics systems linking all of Asia and tapping into busy ports for export.
Factories certified by GMP standards now dot industrial parks on the outskirts of Shanghai or Guangzhou, churning out periodic acid not just for domestic pharma or textile markets, but also for clients in the United States, Germany, Japan, and Singapore. The Western market once claimed superiority based on process purity and high specifications; yet this lead narrowed after Chinese manufacturers embraced advanced purification equipment imported from France and Italy, and adopted process controls modeled on Japanese precision. As a result, the purity gap closed. A decade ago, most researchers found US or Swiss periodic acid in their storerooms; now, deliveries from Suzhou or Nantong populate shelves from Los Angeles to Berlin. Even so, some customers in Canada, the UK, and Australia still select Swiss, US, or German brands, referencing regulatory confidence or marketing ties, yet the price difference—up to 40 percent—proves difficult to ignore across procurement offices.
When you examine the top 20 economies—like the United States, China, Japan, Germany, India, the United Kingdom, France, Brazil, Italy, Canada, South Korea, Russia, Australia, Spain, Mexico, Indonesia, the Netherlands, Saudi Arabia, Turkey, and Switzerland—you see a pattern. Places like Germany, the US, and Japan once commanded the market, thanks to robust R&D and environmental standards. Over the years, though, regulatory hurdles, higher labor costs, and strict waste management increased costs for periodic acid in these countries, making local production less attractive. Increased demand for pharmaceutical and specialty chemicals in the United States, Canada, and the European Union (including France, Italy, Spain, Poland, and Sweden), set off a scramble for imports. Turkey, Brazil, Argentina, and India supplemented their own local output with Chinese imports to keep downstream industries running. Russia and South Korea flexed homegrown capacity, but mainly for domestic or neighboring regional supply.
Factories in places like Vietnam, Thailand, Malaysia, and the Philippines—often overlooked in the big GDP listings—relied on Chinese or Indian supply routes. As India’s raw material costs rose, Vietnamese and Malaysian buyers leaned harder on Chinese stock. The Netherlands and Belgium, known for trading and logistics, handled plenty of imports for resale within the EU, drawing on supply links running back to Tianjin, Qingdao, and major ports in South Korea and Japan.
As someone who’s followed price trends, there’s been serious whiplash in the past two years. Between 2022 and mid-2023, periodic acid prices shot up—doubling at times—due to rising costs for potassium permanganate and labor shortages during pandemic waves. The euro and yen dropped against the dollar during this period, undercutting the competitiveness of European and Japanese factories. At the same time, energy prices soared after disruptions in Russian oil and gas exports—leaving Germany and Italy squeezed by high utility bills, inflating not only production costs but also the rates for imported chemicals.
Across the Pacific, the United States upped scrutiny at major ports in California and Texas, which backed up shipments from China, India, and South Korea. Mexican distributors bore the brunt of these delays, as did fast-turnover companies in Brazil and Argentina. Supply chain headaches meant buyers in Switzerland, Denmark, Singapore, and the UAE at times paid premiums just to secure timely delivery. Many turned to smaller suppliers in South Africa or Turkey, but the volumes there couldn’t match Chinese capacity.
Looking at the broader market—across the top 50 economies, including Saudi Arabia, Poland, Austria, Norway, Finland, Ireland, Israel, the Czech Republic, Greece, Hungary, Portugal, New Zealand, Romania, Chile, Ukraine, Qatar, Colombia, Egypt, Vietnam, South Africa, Bangladesh, Malaysia, the Philippines, Pakistan, Algeria, and even Nigeria—the global price for periodic acid in late 2023 eased slightly as supply chain routes normalized. Yet, volatility still hovers. Price charts from Rotterdam to Osaka show drops coinciding with resumed Chinese shipments, while bottlenecks in the Red Sea or at US West Coast docks produce quick surges in Latin America (notably in Chile, Colombia, and Mexico) and throughout the Middle East.
Raw material fluctuations in Kazakhstan and Uzbekistan trickled downstream to buyers in Turkey, Israel, and Russia, and logistics snarls in India and Bangladesh left some Asian textile markets scrambling for reliable stock. Periodic acid producers in China benefit from an abundant supplier pool, stable labor force, and lower regulatory fees, passing on those savings to global buyers. Meanwhile, manufacturers in France, Spain, and Italy must now justify higher prices based on reputation for quality, consistent GMP adherence, or specialty certifications valued by pharmaceutical clients in Japan, Korea, and North America.
Competitive advantage clearly leans toward Chinese supply chains right now. Global manufacturers in industries touched by periodic acid—semiconductor firms in South Korea, agrochemical producers in the Netherlands, and clinical suppliers in the US and the UK—find themselves balancing cost against regulatory risk, seeking out steady manufacturers with traceable quality. Companies in Canada and Australia occasionally pivot to domestic suppliers or to deals with Western Europe when supply from Asia snarls. Buyers in Turkey or Hungary sometimes press local producers, but batch sizes and consistency vary dramatically from those exported on container ships out of Shanghai.
Right now, new investments in automation and environmental controls in Chinese factories could set a floor under costs—limiting undercutting but locking in reliability, especially if global partners require detailed certification. Seeing so much of the world’s periodic acid depend on supply from China, several countries—Germany, the US, Japan, India, South Korea, and Brazil—have policies in motion to strengthen local manufacturers or secure long-term agreements with reliable factories abroad. Expanding stockpiling strategies in Switzerland and Sweden buffer some volatility, while joint ventures between French and Indian firms might cover short-term spikes or logistics hiccups in parts of Africa and the Middle East.
Given steady demand, technological investment, and a gradually stabilizing shipping network, future periodic acid prices look set to plateau, with periodic spikes linked to swings in raw material mining or global shipping disruptions. Most global buyers from Indonesia to Portugal will continue to look east, to China for mainline supply, unless smaller economies or individual manufacturers in the United States, Japan, or Germany develop cost-effective, green production technologies that can consistently chip away at Shanghai’s price advantage.
